| 1 |
14692025 | A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. | 2004 Jan 1 |
2 |
| 2 |
12177096 | Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. | 2002 Aug 15 |
1 |
| 3 |
11230472 | Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. | 2001 Mar 1 |
3 |
| 4 |
10096380 | Suramin treatment in hormone- and chemotherapy-refractory prostate cancer. | 1999 Mar |
1 |
| 5 |
9676853 | A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. | 1998 Jul |
1 |
| 6 |
8637045 | Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. | 1996 Jun 19 |
8 |
| 7 |
8827086 | The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. | 1996 Sep |
1 |
| 8 |
8995493 | A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. | 1996 |
1 |
| 9 |
8523059 | Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. | 1995 Dec |
1 |